Elanco Animal Health (ELAN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $13.20B
Last updated: Nov 17, 2026 at 4:15 PM ET
Elanco Animal Health (ELAN) Statistics
Elanco Animal Health (ELAN) has a market cap of $13.20B and an enterprise value of $16.44B. Its return on invested capital of 1.58% compares with a 11.58% median across 9 similar companies. Its trailing P/E of 22.7x is above its 5-year median of 16.8x.
Total Valuation
Enterprise value is 24.56% above the market cap, as debt exceeds cash.
| Market Cap | $13.20B |
|---|---|
| Enterprise Value | $16.44B |
| Latest price (Nov 17, 2026) | $25.86 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 6, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.5x and 1.9x. Its year-end P/E ranged from 11.0x to 65.3x from 2019 to 2025.
| P/E Ratio | 22.7x |
|---|---|
| Forward P/E | 21.7x |
| P/S Ratio | 2.5x |
| Forward P/S | 2.5x |
| P/B Ratio | 1.9x |
| P/FCF Ratio | 31.7x |
| P/OCF Ratio | 21.5x |
| PEG Ratio | 2.2 |
Enterprise Valuation
Counting debt and cash, the company is valued at 18.9x EBITDA and 39.6x free cash flow.
| EV / Sales | 3.2x |
|---|---|
| EV / EBITDA | 18.9x |
| EV / EBIT | 100.9x |
| EV / FCF | 39.6x |
Price Statistics
The stock is up 22.62% over 52 weeks and trades 10.28% above its 50-day average.
| Beta (1Y) | 1.32 |
|---|---|
| 52-Week Change | +22.62% |
| 1-Month Change | +10.09% |
| 3-Month Change | +5.55% |
| 6-Month Change | +30.61% |
| 5-Year Change | -29.87% |
| Total Return (1Y) | +22.62% |
| Total Return (3Y CAGR) | +29.81% |
| Total Return (5Y CAGR) | -4.38% |
| Return vs SPY (1Y) | +9.34% |
| Max Drawdown (1Y) | -26.23% |
| Max Drawdown (3Y) | -56.10% |
| Sharpe Ratio (1Y) | 0.44 |
| Correlation with SPY (1Y) | 0.42 |
| 50-Day Average | $23.45 |
| 200-Day Average | $23.87 |
| 52-Week Range | $19.40 to $27.98 |
| RSI (14 Days) | 59.1 |
| Average Volume (20 Days) | 5.38M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.09x current liabilities, and total debt is 0.56x shareholder equity.
| Current Ratio | 2.09x |
|---|---|
| Quick Ratio | 1.07x |
| Debt / Equity | 0.56x |
| Debt / EBITDA | 4.33x |
| Debt / FCF | 9.09x |
| Interest Coverage | 0.64x |
Returns and Efficiency
Return on invested capital is 1.58% over the last 12 months, against a 5-year average of -0.73%.
| Return on Equity (ROE) | -2.22% |
|---|---|
| Return on Assets (ROA) | -1.10% |
| Return on Invested Capital (ROIC) | 1.58% |
| Return on Capital Employed (ROCE) | 1.41% |
| ROE (5Y Average) | -5.06% |
| ROA (5Y Average) | -2.21% |
| ROIC (5Y Average) | -0.73% |
| Asset Turnover | 0.38x |
| Inventory Turnover | 1.26x |
| Receivables Turnover | 4.65x |
| Cash Conversion Cycle | 301 days |
Scores
ELAN has an Altman Z-Score of 1.54, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.54 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $5.15B over the last 12 months is up 12.13% from the 12 months before.
| Revenue | $5.15B |
|---|---|
| Revenue Growth (YoY) | +12.13% |
| Gross Profit | $2.89B |
| Operating Income | $140.00M |
| Pretax Income | -$92.00M |
| Net Income | -$147.00M |
| EBITDA | $857.00M |
| EBIT | $163.00M |
| Reported EPS (TTM) | $1.14 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 49.70% of the $13.34B in total assets.
| Cash and Equivalents | $465.00M |
|---|---|
| Total Debt | $3.71B |
| Net Debt | $3.24B |
| Net Debt Per Share | $6.49 |
| Working Capital | $1.94B |
| Shareholder Equity | $6.63B |
| Book Value Per Share | $13.26 |
| Tangible Book Value | -$1.20B |
| Total Assets | $13.34B |
| Total Liabilities | $6.71B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $206.00M of capital spending, operating cash flow left $408.00M of free cash flow.
| Operating Cash Flow | $614.00M |
|---|---|
| Capital Expenditures | $206.00M |
| Free Cash Flow | $408.00M |
| FCF Per Share | $0.82 |
| Depreciation and Amortization | $694.00M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 2.72%, against a 5-year average of -4.44%.
| Gross Margin | 56.18% |
|---|---|
| Operating Margin | 2.72% |
| Pretax Margin | -1.79% |
| Net Margin | -2.86% |
| EBITDA Margin | 16.65% |
| EBIT Margin | 3.17% |
| FCF Margin | 7.93% |
| Gross Margin (5Y Average) | 55.61% |
| Operating Margin (5Y Average) | -4.44% |
| Net Margin (5Y Average) | -7.42% |
Growth
Revenue grew 2.25% a year over 3 years, and EPS fell 5.06% a year.
| Revenue Growth (3Y CAGR) | +2.25% |
|---|---|
| Revenue Growth (5Y CAGR) | +7.59% |
| EPS Growth (3Y CAGR) | -5.06% |
| EPS Growth (5Y CAGR) | +15.11% |
| FCF Growth (3Y CAGR) | +0.35% |
| Book Value Per Share Growth (2Y CAGR) | +2.15% |
Dividends and Yields
ELAN does not pay a dividend. Its free cash flow yield is 3.16%.
| Earnings Yield | 4.41% |
|---|---|
| FCF Yield | 3.16% |
| Shareholder Yield | 0.00% |
Peer Position
Against 10 similar companies, ELAN has the 3rd highest P/E.
P/E RatioPeer median 18.2x
P/S RatioPeer median 3.2x
ROICPeer median 11.58%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +4.27%
| P/E Ratio | 22.7x vs 18.2x median |
|---|---|
| P/S Ratio | 2.5x vs 3.2x median |
| ROIC | 1.58% vs 11.58% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +12.13% vs +4.27% median |
Analyst Forecast
Consensus estimates put revenue growth at 7.50% and EPS growth at 16.56% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +7.50% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +16.56% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ELAN
What is ELAN's market cap?
Elanco Animal Health has a market cap of $13.20B. Its enterprise value, which adds debt and subtracts cash, is $16.44B.
What is ELAN's P/E ratio?
Elanco Animal Health has a trailing P/E ratio of 22.7x and a forward P/E of 21.7x.
How many shares of ELAN are outstanding?
Elanco Animal Health has 499.70M shares outstanding. The count is up 0.58% from a year earlier.
Does ELAN pay a dividend?
No. Elanco Animal Health does not pay a dividend.
How much debt does ELAN have?
Elanco Animal Health has $3.71B of total debt and $465.00M of cash and equivalents, a net debt position of $3.24B.
ELAN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors